What do systematic reviews say?

Tranexamic acid vs placebo (saline solution or sterile water)

Tranexamic acid showed no clear difference in significant adverse events (seizures, thromboembolism) within 24… compared with placebo (saline solution or sterile water) (moderate certainty).

• Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery 2023 · Cochrane Headline outcomes only
  RD 0
  8 studies · 664 participants
  Moderate

Tranexamic acid vs placebo

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 12 participants
  Very low

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes

  Up to 10 days postoperative
  RD 0.034 [-0.32, 0.38]
  2 studies · 59 participants
  Low

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in side effects or other adverse events requiring withdrawal compared with placebo (placebo solution/mouthwash) (moderate certainty).

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes

  7 days
  RD 0.00 [-0.04, 0.04]
  2 studies · 128 participants
  Moderate

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo or usual care

Topical TXA showed no clear difference in adverse event compared with no TXA (placebo or usual care) (moderate certainty).

• Tranexamic acid for percutaneous nephrolithotomy 2023 · Cochrane Headline outcomes only
  RD 0
  1 study · 400 participants
  Moderate

Systemic TXA vs placebo or usual care

Systemic TXA showed no clear difference in adverse events compared with no TXA (placebo or usual care) (low certainty).

• Tranexamic acid for percutaneous nephrolithotomy 2023 · Cochrane Headline outcomes only
  RR 5.22 [0.52, 52.72]
  4 studies · 602 participants
  Low